Table 2.

Predicted versus observed plasma pharmacokinetics of efavirenz and thalidomide in non-pregnant adults.

Parameters	Observed	Predicted	Predicted/observed ratio
Efavirenza	(Dickinson et al., 2016) n = 605	n = 100
400 mg
C12 (mg/L)	2.10 (2.01–2.20)	1.86 (1.65–2.06)	0.89
C24 (mg/L)	1.40 (1.32–1.49)	1.30 (1.10–1.49)	0.93
Cmax (mg/L)	2.52 (2.42–2.62)	2.47 (2.27–2.67)	0.98
AUC0–24 (mg.h/L)	49.2 (47.0–51.5)	42.6 (38.0–47.2)	0.87
600 mg
C12 (mg/L)	2.85 (2.70–3.0)	2.93 (2.59–3.27)	1.0
C24 (mg/L)	1.82 (1.68–1.97)	2.07 (1.75–2.40)	1.1
Cmax (mg/L)	3.66 (3.51–3.81)	3.86 (3.52–4.20)	1.1
AUC0–24 (mg.h/L)	67.2 (63.8–70.9)	67.3 (59.5–75.0)	1.0
Thalidomideb	Thalomid Label_FDA (2001)	n = 100
200 mg
Cmax (mg/L)	1.76 (30)	2.15 (17.7)	1.2
AUC0–24 (mg.h/L)	18.9 (17)	16.1 (18.6)	0.85
400 mg
Cmax (mg/L)	2.82 (28)	4.33 (18.2)	1.5
AUC0–24 (mg.h/L)	36.4 (26)	32.4 (18.5)	0.89

^aMean (90% CI) at steady-state.

^bMean (%CV) after single dose.